Francis P. Crawley

Mr. Francis P. Crawley

Good Clinical Practice Alliance - Europe (GCPA)
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in EBioMedicine
Verified
Journal Article
Open access
MBMargherita Baldassarri
Margherita Baldassarri
NPnicola picchiotti
nicola picchiotti
FFFrancesca Fava
Francesca Fava
CFChiara Fallerini
Chiara Fallerini
EBElisa Benetti
Elisa Benetti
GPGianfranco Parati
Gianfranco Parati
While SARS-CoV-2 similarly infects men and women, COVID-19 outcome is less favorable in men. Variability in COVID-19 severity may be explained by differences in the host genome. We compared poly-amino acids variability from WES data in severely affected COVID-19 patients versus SARS-CoV-2 PCR-positive oligo-asymptomatic subjects. Shorter polyQ alleles (≤22) in the androgen receptor (AR) conferred protection against severe outcome in COVID-19 in the first tested cohort (both males and females) of 638 Italian subjects. The association between long polyQ alleles (≥23) and severe clinical outcome (p = 0.024) was also validated in an independent cohort of Spanish men <60 years of age (p = 0.014). Testosterone was higher in subjects with AR long-polyQ, possibly indicating receptor resistance (p = 0.042 Mann-Whitney U test). Inappropriately low serum testosterone level among carriers of the long-polyQ alleles (p = 0.0004 Mann-Whitney U test) predicted the need for intensive care in COVID-19 infected men. In agreement with the known anti-inflammatory action of testosterone, patients with long-polyQ and age ≥60 years had increased levels of CRP (p = 0.018, not accounting for multiple testing). We identify the first genetic polymorphism that appears to predispose some men to develop more severe disease. Failure of the endocrine feedback to overcome AR signaling defects by increasing testosterone levels during the infection leads to the polyQ tract becoming dominant to serum testosterone levels for the clinical outcome. These results may contribute to designing reliable clinical and public health measures and provide a rationale to test testosterone as adjuvant therapy in men with COVID-19 expressing long AR polyQ repeats. MIUR project “Dipartimenti di Eccellenza 2018-2020” to Department of Medical Biotechnologies University of Siena, Italy (Italian D.L. n.18 March 17, 2020) and “Bando Ricerca COVID-19 Toscana” project to Azienda Ospedaliero-Universitaria Senese. Private donors for COVID-19 research and charity funds from Intesa San Paolo.

17 January 2021 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
GSGEN-COVID Multicenter Study
GEN-COVID Multicenter Study
SDSergio Daga
Sergio Daga
CFChiara Fallerini
Chiara Fallerini
MBMargherita Baldassarri
Margherita Baldassarri
FFFrancesca Fava
Francesca Fava
EFElisa Frullanti
Elisa Frullanti
Within the GEN-COVID Multicenter Study, biospecimens from more than 1000 SARS-CoV-2 positive individuals have thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum, leukocytes, and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O2supplementation, and without respiratory support (9.5%, 18.4%, 31.55% and 14.8, respectively); and non-hospitalized subjects (25.75%), either pauci- or asymptomatic. More than 150 clinical patient-level data fields have been collected and binarized for further statistics according to the organs/systems primarily affected by COVID-19: heart, liver, pancreas, kidney, chemosensors, innate or adaptive immunity, and clotting system. Hierarchical clustering analysis identified five main clinical categories: (1) severe multisystemic failure with either thromboembolic or pancreatic variant; (2) cytokine storm type, either severe with liver involvement or moderate; (3) moderate heart type, either with or without liver damage; (4) moderate multisystemic involvement, either with or without liver damage; (5) mild, either with or without hyposmia. GCB and GCPR are further linked to the GCGDR, which includes data from whole-exome sequencing and high-density SNP genotyping. The data are available for sharing through the Network for Italian Genomes, found within the COVID-19 dedicated section. The study objective is to systematize this comprehensive data collection and begin identifying multi-organ involvement in COVID-19, defining genetic parameters for infection susceptibility within the population, and mapping genetically COVID-19 severity and clinical complexity among patients.

22 November 2017 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
Artur MazurArtur Mazur
Artur Mazur
MCMargherita Caroli
Margherita Caroli
IRIgor Radziewicz-Winnicki
Igor Radziewicz-Winnicki
PNPaulina Nowicka
Paulina Nowicka
DWDaniel Weghuber
Daniel Weghuber
Adamos HadjipanayisAdamos Hadjipanayis
Adamos Hadjipanayis

6 May 2021 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
DHDara Hallinan
Dara Hallinan
ABAlexander Bernier
Alexander Bernier
ACAnne Cambon-Thomsen
Anne Cambon-Thomsen
Francis P. CrawleyFrancis P. Crawley
Francis P. Crawley
DDDiana Dimitrova
Diana Dimitrova
SRStéphanie Rennes
Stéphanie Rennes
On 16 July 2020, the Court of Justice of the European Union issued their decision in the Schrems II case concerning Facebook’s transfers of personal data from the EU to the US. The decision may have significant effects on the legitimate transfer of personal data for health research purposes from the EU. This article aims: (i) to outline the consequences of the Schrems II decision for the sharing of personal data for health research between the EU and third countries, particularly in the context of the COVID-19 pandemic; and, (ii) to consider certain options available to address the consequences of the decision and to facilitate international data exchange for health research moving forward.

12 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
Keneth Iceland KasoziKeneth Iceland Kasozi
Keneth Iceland Kasozi
Anne LaudisoitAnne Laudisoit
Anne Laudisoit
LOLawrence, Obado Osuwat
Lawrence, Obado Osuwat
Gaber El-Saber BatihaGaber El-Saber Batiha
Gaber El-Saber Batiha
NONaif E. Al Omairi
Naif E. Al Omairi
Keneth Iceland KasoziKeneth Iceland Kasozi
Keneth Iceland Kasozi
Background—misinformation and mistrust often undermines community vaccine uptake, yet information in rural communities, especially of developing countries, is scarce. This study aimed to identify major challenges associated with coronavirus disease 2019 (COVID-19) vaccine clinical trials among healthcare workers and staff in Uganda. Methods—a rapid exploratory survey was conducted over 5 weeks among 260 respondents (66% male) from healthcare centers across the country using an online questionnaire. Twenty-seven questions assessed knowledge, confidence, and trust scores on COVID-19 vaccine clinical trials from participants in 46 districts in Uganda. Results—we found low levels of knowledge (i.e., confusing COVID-19 with Ebola) with males being more informed than females (OR = 1.5, 95% CI: 0.7–3.0), and mistrust associated with policy decisions to promote herbal treatments in Uganda and the rushed international clinical trials, highlighting challenges for the upcoming Oxford–AstraZeneca vaccinations. Knowledge, confidence and trust scores were higher among the least educated (certificate vs. bachelor degree holders). We also found a high level of skepticism and possible community resistance to DNA recombinant vaccines, such as the Oxford–AstraZeneca vaccine. Preference for herbal treatments (38/260; 14.6%, 95% CI: 10.7–19.3) currently being promoted by the Ugandan government raises major policy concerns. High fear and mistrust for COVID-19 vaccine clinical trials was more common among wealthier participants and more affluent regions of the country. Conclusion—our study found that knowledge, confidence, and trust in COVID-19 vaccines was low among healthcare workers in Uganda, especially those with higher wealth and educational status. There is a need to increase transparency and inclusive participation to address these issues before new trials of COVID-19 vaccines are initiated.

11 September 2024 in Cell Research
Verified
Journal Article
Open access
PDF file
WLWeibin Liu
Weibin Liu
YLYan Li
Yan Li
GPGeorge P. Patrinos
George P. Patrinos
SXShuhua Xu
Shuhua Xu
MTMeow-Keong Thong
Meow-Keong Thong
XXXun Xu
Xun Xu